For patients who recur on anti–PD-1, they should be considered resistant to anti–PD-1 and must change to a different type of medication, said Dr Owen.
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
Among those who had not received prior treatment, overall survival was 23.2% after 5 years.
The investigators said the data justify and support the submission of enfortumab vedotin for consideration under FDA’s accelerated approval pathway.
Initial therapy with pembrolizumab may result in comparable overall survival as standard chemotherapy in patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.
The median duration of response to olaparib in these patients with metastatic pancreatic cancer was more than 2 years.
Cancer drugs approved with a breakthrough therapy designation may be more or equally likely to demonstrate high clinical benefit compared with non-breakthrough therapy drugs.
The VISNU-1 trial is “the first study performed in a population selected by baseline [circulating tumor cell] count,” according to lead study author Javier Sastre, MD, PhD.
A significantly greater proportion of patients in the flumatinib group had a complete molecular response at 12 months compared with in the imatinib group.
Pembrolizumab improved PFS in this high-risk patient population, but a randomized controlled trial is warranted.
